Skip to main content

What causes therapy-related malignancies in childhood cancer survivors? Dissecting the etiology of second cancers

Project description

Insight into therapy-related malignancies

Childhood cancer survivors often present with therapy-related malignancies as a result of exposure to chemotherapy or radiotherapy. However, the mechanistic details of how these secondary malignancies emerge are poorly understood. The scope of the EU-funded SecondCANCERinKIDS project is to investigate how mutations accumulate in hematopoietic stem cells and give rise to therapy-related myeloid malignancies (t-MNs). For this purpose, scientists will study hematopoietic cell lineages in children before and after they receive chemotherapy to determine whether the malignant clones pre-existed or were generated as a consequence of treatment. The results will show how chemotherapy affects blood composition and provide novel insights into the origin of cancer.

Host institution

PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV
Net EU contribution
€ 2 000 000,00
Address
Heidelberglaan 25
3584CS Utrecht
Netherlands

See on map

Region
West-Nederland Utrecht Utrecht
Activity type
Other
Other funding
€ 0,00

Beneficiaries (1)

PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV
Netherlands
Net EU contribution
€ 2 000 000,00
Address
Heidelberglaan 25
3584CS Utrecht

See on map

Region
West-Nederland Utrecht Utrecht
Activity type
Other
Other funding
€ 0,00